An evolutionary continuum from nucleated dwarf galaxies to star clusters.

Systematic studies have revealed hundreds of ultra-compact dwarf galaxies (UCDs) in the nearby Universe. With half-light radii r of approximately 10-100 parsecs and stellar masses M≈ 10-10solar masses, UCDs are among the densest known stellar systems. Although similar in appearance to massive globular clusters, the detection of extended stellar envelopes, complex star formation histories, elevated mass-to-light ratio and supermassive black holes suggest that some UCDs are remnant nuclear star clusters of tidally stripped dwarf galaxies, or even ancient compact galaxies.

Patient satisfaction, experience and preferences in the implementation of genetics teleconsultations in the North-eastern region of France.

Introduction: In France, few centres per region offer genetics consultations. Consequently, each centre covers a large area, often requiring patients to take a day off to travel long distances. In certain situations, genetic counselling in particular, a physical exam is not required.

Advancing precision oncology through systematic germline and tumor genetic analysis: The oncogenetic point of view on findings from a prospective multicenter clinical trial of 666 patients.

Introduction: With the emergence of targeted therapies, there is a need to accurately identify more tumor biomarkers. The EXOMA trial was designed to offer tumor and germline exome sequencing (ES) to patients with solid malignant tumors and facing therapeutic failure. As hereditary cancer predispositions could be identified, with genetic counseling and health management implications, a genetic consultation was systematically established.

Incidental findings in a series of 2500 gene panel tests for a genetic predisposition to cancer: Results and impact on patients.

With next generation sequencing, physicians are faced with more complex and uncertain data, particularly incidental findings (IF). Guidelines for the return of IF have been published by learned societies. However, little is known about how patients are affected by these results in a context of oncogenetic testing.